brian caulkins

Go Blue〽️. #xrparmy 👨‍✈️🛫

[🏠 BOXABL 🏭 Galiano Tiramani @GalianoTiramani]

New product lineup ✅
New product order ✅
@BOXABL

[BOXABL @BOXABL]

BOXABL Announces First Phase 2 Order with Shelton Development for 203 Boxes in Texas

[Paolo Tiramani @PaoloTiramani]

Developer beta is live! 100 unit min. It’s buggy, it’s basic, but fark 3 boxes make EVERYTHING residential. Upcoming features will be 🤯. Housing 🧬 rebuilt: lowest cost, max speed & design, best quality. Take a look pls 💩 away to make us 💪🏼 @BOXABL
https://t.co/WFMTsoc1TU

[FSU Baseball @FSUBaseball]

Call in sick, take an extra-long lunch break, cancel that afternoon meeting. 🤷

Whatever it takes, we need you at Howser this afternoon!

[brian caulkins @bdc5222]

@peter_torngren Emisphere solved it. Novo bought it. Let’s be truthful here. $EMIS $NVO #facts

[Hspooner @Hspooner665]

A great message from a poster on the New $NWBO community message board.🤟😁

[D3TRO1TJOK3R @D3TRO1TJOK3R]

Nothing says ‘I knew it was over’ more than Donovan Edwards two explosive TD runs in Columbus 🔥

[BOXABL @BOXABL]

Our mission is to solve the housing crisis

[The Fox Radar @TheFoxRadar]

Why $PRME investors should pay attention to what happened on May 25

On May 25, 2026, Eli Lilly published Phase 1b results in NEJM for VERVE-102, an in vivo base editor delivered via LNP-GalNAc to the liver in patients with familial hypercholesterolemia.

The results: 88% reduction in PCSK9 and up to 69% reduction in LDL-C with a single dose. No serious treatment-related adverse events. No clinically significant ALT elevations. No thrombocytopenia. Across 14 consecutive patients.

VERVE-102 validates in humans the LNP-GalNAc delivery modality for genome editors in the liver. It is the first clinical demonstration that this system works with clean safety in real patients, not just in non-human primates.

Prime Medicine uses the same concept: LNP with GalNAc ligand targeting hepatocytes via ASGPR receptor. PM577 (Wilson Disease) and PM647 (AATD) depend on this delivery modality to bring the prime editor to the liver.

The Verve precedent significantly de-risks PM577 ahead of 2027 clinical data. It does not eliminate risk, Prime executes precise point correction, technically more demanding than Verve’s knockout approach, and uses a distinct proprietary LNP formulation, but the underlying modality is now clinically validated.

Adding to this are the scientific improvements in prime editing published in 2024-2025: PE7 (La protein fused to the editor to protect the pegRNA) reaches 47% editing with a single dose in mouse liver vs 26% with PEmax. PRIDICT2.0 enables computational pegRNA design with 8 of 11 PKU mutations exceeding the reference in vitro.

These improvements likely do not apply integrally to PM577 (IND-enabling timeline does not fit), but they indicate that the prime editing efficiency curve continues to accelerate. Programs entering IND-enabling in 2026-2027 may incorporate PE7 directly.

But the central question of the thesis: does LNP-GalNAc work for gene editing in human liver? now has an affirmative clinical answer from Verve. That materially reduces the binary risk Prime Medicine faces in its upcoming catalysts.

[J Keynes @JKeynesAlpha]

$TEM

[FSU Baseball @FSUBaseball]

Ball four. Game over. The Noles take game one.😆

[J Keynes @JKeynesAlpha]

$TEM For some reason the market is just ignoring Tempus and health care AI theme, despite the fact that to those who pay attention, it's getting giant and set for a major run. Won't repost my numerous DDs, which you can find easily. Patience friends. The time is coming.

[FSU Baseball @FSUBaseball]

Two strikeouts in the 4th, Gabe Nard has retired all 6 batters he's faced.

E-4, FSU 1, UNF 0

[BOXABL @BOXABL]

😎

[FSU Baseball @FSUBaseball]

This week in the national rankings 📈

[FSU Baseball @FSUBaseball]

The series was won with a 12-11 victory on Saturday, beginning with a four-run first inning. Three bases-loaded walks in the seventh added insurance runs before Gabe Nard closed it out for his first save.

[Brett Nevitt @brettpn]

Gabe Nard gets a K looking to strand the tying run on third. FSU wins the series.

FINAL: FSU 12, Duke 11

[Dicky Chan @FatboyChan74370]

Big news. Target price $1 within 12 months
NWBO😍
https://t.co/4mN6pSC59S